Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Johns Hopkins Medicine · Johns Hopkins University · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
707
total citations
- FWCI
- 46.23
- Percentile
- 100%
- References
- 49
Citations per year
Authors
24- CLCornelia L. TrimbleCorresponding
Johns Hopkins Medicine, Johns Hopkins University
- MPMatthew P. Morrow
Inovio Pharmaceuticals (United States)
- KAKimberly A. Kraynyak
Inovio Pharmaceuticals (United States)
- XSXuefei Shen
Inovio Pharmaceuticals (United States)
- MDMichael Dallas
Inovio Pharmaceuticals (United States)
Topics & keywords
Topics
Keywords
- Medicine
- Cervical intraepithelial neoplasia
- Placebo
- Clinical endpoint
- Population
- Internal medicine
- Cervical cancer
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.